Literature DB >> 29907621

Heroin Use Is Associated with AA-Type Kidney Amyloidosis in the Pacific Northwest.

Arjun Sharma1, Priyanka Govindan1, Mirna Toukatly2, Jack Healy3, Connor Henry3, Steve Senter4, Behzad Najafian2, Bryan Kestenbaum5,3.   

Abstract

BACKGROUND AND OBJECTIVES: AA-type kidney amyloidosis is classically associated with chronic autoimmune or inflammatory disorders. However, some urban centers have reported a high prevalence of injection drug use among patients with kidney AA amyloidosis. Previous reports lack control groups to quantify associations and most predate the opioid epidemic in the United States. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a case-control study of 38 patients with biopsy-confirmed kidney AA amyloidosis and 72 matched control individuals without this condition from two large hospital systems in Seattle, Washington. We ascertained the pattern and duration of heroin use by medical chart review and determined associations using logistic regression.
RESULTS: Among case patients, 95% had a prior history of heroin use, 87% had skin abscesses, and 76% and 27% had evidence of muscling and skin popping, respectively. After adjustment for age, race, sex, site, and year of biopsy, any heroin use (past or current) was associated with an estimated 170-times higher risk of kidney AA amyloidosis compared with no heroin use (95% confidence interval, 28 to 1018 times higher; P<0.001). Chronic autoimmune disorders were uncommon among case patients in this study. The median time to ESKD among patients with AA amyloidosis was 2.4 years (interquartile range, 0.5-7.5 years).
CONCLUSIONS: Injection heroin use is strongly associated with kidney AA amyloidosis in the Pacific Northwest. Unique aspects of heroin use, in particular geographic regions or frequent associated soft-tissue infections, may be an important cause of this progressive kidney disease.
Copyright © 2018 by the American Society of Nephrology.

Entities:  

Keywords:  Abscess; Amyloidosis; Biopsy; Case-control Studies; Confidence Intervals; Control Groups; Heroin; Humans; Kidney Failure, Chronic; Logistic Models; Prednisolone; Prevalence; Soft Tissue Infections; Washington; chronic kidney disease; dialysis; kidney; nephrotic syndrome

Year:  2018        PMID: 29907621      PMCID: PMC6032593          DOI: 10.2215/CJN.13641217

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  20 in total

1.  Significant association between renal function and area of amyloid deposition in kidney biopsy specimens in both AA amyloidosis associated with rheumatoid arthritis and AL amyloidosis.

Authors:  Takeshi Kuroda; Naohito Tanabe; Eriko Hasegawa; Ayako Wakamatsu; Yukiko Nozawa; Hiroe Sato; Takeshi Nakatsue; Yoko Wada; Yumi Ito; Naofumi Imai; Mitsuhiro Ueno; Masaaki Nakano; Ichiei Narita
Journal:  Amyloid       Date:  2017-06-14       Impact factor: 7.141

2.  AA amyloidosis: Mount Sinai experience, 1997-2012.

Authors:  Daniel Bunker; Peter Gorevic
Journal:  Mt Sinai J Med       Date:  2012 Nov-Dec

3.  AA protein-related renal amyloidosis in drug addicts.

Authors:  S Menchel; D Cohen; E Gross; B Frangione; G Gallo
Journal:  Am J Pathol       Date:  1983-08       Impact factor: 4.307

Review 4.  Systemic amyloidosis.

Authors:  Ashutosh D Wechalekar; Julian D Gillmore; Philip N Hawkins
Journal:  Lancet       Date:  2015-12-21       Impact factor: 79.321

5.  Characteristics of AA amyloidosis patients in San Francisco.

Authors:  Hiba Lejmi; Kuang-Yu Jen; Jean L Olson; Sam H James; Ramin Sam
Journal:  Nephrology (Carlton)       Date:  2016-04       Impact factor: 2.506

6.  Presentation, survival and prognostic markers in AA amyloidosis.

Authors:  N Joss; K McLaughlin; K Simpson; J M Boulton-Jones
Journal:  QJM       Date:  2000-08

7.  Amyloidosis in chronic heroin addicts with the nephrotic syndrome.

Authors:  J Scholes; R Derosena; G B Appel; W Jao; M T Boyd; C L Pirani
Journal:  Ann Intern Med       Date:  1979-07       Impact factor: 25.391

8.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

9.  Natural history and outcome in systemic AA amyloidosis.

Authors:  Helen J Lachmann; Hugh J B Goodman; Janet A Gilbertson; J Ruth Gallimore; Caroline A Sabin; Julian D Gillmore; Philip N Hawkins
Journal:  N Engl J Med       Date:  2007-06-07       Impact factor: 91.245

10.  Murine model for human secondary amyloidosis: genetic variability of the acute-phase serum protein SAA response to endotoxins and casein.

Authors:  K P McAdam; J D Sipe
Journal:  J Exp Med       Date:  1976-10-01       Impact factor: 14.307

View more
  3 in total

1.  The Changing Spectrum of Heroin-Associated Kidney Disease.

Authors:  Sanjeev Sethi
Journal:  Clin J Am Soc Nephrol       Date:  2018-06-15       Impact factor: 8.237

2.  Systemic AA Amyloidosis Associated With Intravenous Injection of Oral Prescription Opioids-An Autopsy Case Report.

Authors:  Kenneth M Zabel; Grace Y Lin; Rebecca E Sell; Omonigho Aisagbonhi
Journal:  Am J Forensic Med Pathol       Date:  2021-09-10       Impact factor: 1.108

3.  Secondary amyloidosis associated with heroin use and recurrent infections - A case report.

Authors:  Deepthi Mani
Journal:  Ann Med Surg (Lond)       Date:  2018-11-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.